47inc
Initiated as a spin out based on an Oxford-Stanford collaboration lead by Irv Wiessman, Oxford cancer researchers developed and delivered the haematological malignancy study that provided the first evidence of benefit for targeting CD47. This was a challenging study with significant toxicity liability that relied on supporting the co-design of a complementary pre-clinical package to enable regulatory approval. Subsequent developments have focused on blood cancers and they are in the process of being bought out by Gilead for $4.9B.